meta_pixel
Tapesearch Logo
Log in
The Excerpt

SPECIAL | Why Americans are making homegrown GLP-1s

The Excerpt

USA TODAY

News, Daily News

4.11.2K Ratings

🗓️ 15 October 2025

⏱️ 13 minutes

🧾️ Download transcript

Summary

High costs. Limited supply. No insurance coverage. All of these are motivating some patients to cook up unregulated “gray GLP-1” drugs at home. Health experts are worried. Why are people willing to risk injecting homemade drugs in an unregulated, non-sterile medical environment and what needs to change before access and safety improve? USA TODAY Wellness Reporter Nicole Fallert joins The Excerpt to share her reporting on this alarming trend.

Have feedback on the show? Please send us an email at podcasts@usatoday.com

Episode transcript available here


See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Transcript

Click on a timestamp to play from that location

0:00.0

Hello and welcome to a special episode of USA Today's The Excerpt.

0:08.1

I'm Dana Taylor.

0:12.9

A growing number of Americans are turning their kitchens into makeshift labs and mixing their own versions of weight loss drugs like OZempec.

0:25.7

They're called gray GLP-1s and they're unregulated, illegal, and increasingly popular.

0:32.1

For some, it's a way to bypass high costs and limited access.

0:35.8

But for doctors and legal experts, it's a troubling

0:38.9

trend that raises questions about safety and oversight. USA Today wellness reporter, Nicole

0:44.5

Fowler, looked into this underground market and what's driving people to take these risks.

0:50.6

Nicole, thank you so much for joining me. Hi, Dana. Happy to be here. Experts you interviewed were clear. These drugs are illegal and unregulated. First, what's

1:00.8

driving this trend is it simply the outsized cost associated with the GLP1 drugs?

1:07.7

I think what's really driving the trend not only is the cost, right? It's a few hundred

1:13.3

dollars to get a brand name drug like Wagovi or Zembek, but also that insurance doesn't

1:21.5

always cover that. I spoke with one mom in Alabama who really wanted to lose some weight postpartum, but because of her

1:30.2

base weight and her background health conditions, she wasn't able to qualify for coverage.

1:35.8

So that was going to look like a few thousand dollars a year for her to be able to lose a few

1:40.3

pounds. So that is a big motivator. There's also the look at people who have maybe been on a

1:47.7

brand name, GLP1 for some time, and they no longer want to pay that higher cost. And they're looking

1:54.4

for a maintenance option to keep up with some of the health benefits that they've been able to get

2:00.7

from the drug. And there's also

2:02.6

people who are stockpiling during supply gaps that are facing manufacturers of brand names

2:10.3

trying to keep up with high demand, right? So they're worried about not being able to get that

2:15.3

drug in time, and they're looking for something to fill gaps.

...

Please login to see the full transcript.

Disclaimer: The podcast and artwork embedded on this page are from USA TODAY, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of USA TODAY and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.

Copyright © Tapesearch 2026.